Rat brain angiotensin II receptors: effects of intracerebroventricular angiotensin II infusion

Sex-Specific Modulation of Blood Pressure and the Renin-Angiotensin System by ACE (Angiotensin-Converting Enzyme) 2

We showed ACE (angiotensin-converting enzyme) 2 is higher in the kidney of male compared with female mice. To further investigate this sex difference, we examined the role of ACE2 in Ang-[1-8] (angiotensin [1-8])-induced hypertension and regulation of the renin-angiotensin system in the kidney of WT (wild type) and Ace2 KO (knockout) mice. Mean arterial pressure rose faster in WT male than WT female mice after Ang-[1-8] infusion. This sex difference was attenuated in ACE2 KO mice. Ang-[1-8] infusion reduced glomerular AT1R (angiotensin type 1 receptor) binding in WT female mice by 30%, and deletion of Ace2 abolished this effect. In contrast, Ang-[1-8] infusion increased glomerular AT1R binding in WT male mice by 1.2-fold, and this effect of Ang-[1-8] persisted in Ace2 KO male mice (1.3-fold). ACE2 also had an effect on renal protein expression of the neutral endopeptidase NEP (neprilysin), the enzyme that catabolizes Ang-[1-10] (angiotensin [1-10]), the precursor of Ang-[1-8]. Ang-[1-8] infusion downregulated NEP protein expression by 20% in WT male, whereas there was a slight increase in NEP expression in WT female mice. Deletion of Ace2 resulted in lowered NEP expression after Ang-[1-8] infusion in both sexes. These findings suggest sex-specific ACE2 regulation of the renin-angiotensin system contributes to female protection from Ang-[1-8]-induced hypertension. These findings have ramifications for the current coronavirus disease 2019 (COVID-19) pandemic, especially in hypertension since ACE2 is the SARS-CoV-2 receptor and hypertension is a major risk factor for poor outcomes.

Differential effects of angiotensin II and angiotensin-(1-7) at the nucleus tractus solitarii of transgenic rats with low brain angiotensinogen

OBJECTIVES

In this study, we investigated the effects of angiotensin II and angiotensin-(1-7) at the nucleus tractus solitarii (nTS) in transgenic rats with a severe deficit in brain angiotensinogen production, TGR(ASrAOGEN) (TGR).

METHODS

Angiotensin II (10 pmol), angiotensin-(1-7) (10 pmol) or NaCl (0.9%/50 nl) were microinjected into the nTS of urethane-anaesthetized TGR (n = 36) and Sprague Dawley (SD) (n = 34) rats. Mean arterial pressure (MAP) and heart rate were measured via a femoral artery catheter and the baroreflex control of heart rate was evaluated after increases in MAP induced by phenylephrine (baroreflex bradycardia).

RESULTS

Angiotensin II microinjections into the nTS of the TGR induced a higher decrease in MAP and heart rate (-37 +/- 5 mmHg and -69 +/- 12 b.p.m., respectively) in comparison to SD rats (-18 +/- 1 mmHg and -43 +/- 5 b.p.m., respectively). In contrast, changes after angiotensin-(1-7) microinjections into the nTS of TGR (-6 +/- 1 mmHg and -13 +/- 4 b.p.m.) were significantly smaller than that induced in SD (-11 +/- 2 mmHg and -24 +/- 6 b.p.m.). The baseline baroreflex sensitivity to phenylephrine of TGR was accentuated in comparison to SD rats (0.70 +/- 0.06 versus 0.44 +/- 0.03 ms/mmHg). Angiotensin II microinjection into the nTS produced similar attenuation in the baroreflex bradycardia in both SD (0.28 +/- 0.07 versus 0.5 +/- 0.07 ms/mmHg, before injection) and TGR (0.44 +/- 0.1 versus 0.82 +/- 0.1 ms/mmHg, before injection). In contrast, angiotensin-(1-7) microinjection elicited a facilitation of the baroreflex bradycardia in SD (0.68 +/- 0.12 versus 0.41 +/- 0.03 ms/mmHg, before injection), while in TGR, angiotensin-(1-7) induced an attenuation of baroreflex bradycardia (0.34 +/- 0.07 ms/mmHg versus 0.55 +/- 0.05 ms/mmHg, before injection).

CONCLUSIONS

These results indicate that a permanent inhibition of angiotensinogen synthesis in the brain can lead to an increase in the sensitivity of the baroreflex control of heart rate (baroreflex bradycardia) and an increase in angiotensin II responsiveness at the nTS. However, the nTS effect of angiotensin-(1-7) was significantly attenuated in these transgenic rats. These data further indicate that the decrease in brain angiotensins in the transgenic rats may be functionally relevant and support the concept of differential regulatory mechanisms for the effects of the two angiotensin peptides.

Central AT1 and AT2 receptors mediate chronic intracerebroventricular angiotensin II-induced drinking in rats fed high sodium chloride diet from weaning

Intracerebroventricular (ICV) angiotensin (AIl) administration stimulates central AII receptors to induce water consumption in rats. The aim of this study was to determine the role of brain AT1 and AT2 receptors in mediating chronic ICV AII-induced drinking in rats raised on normal or high sodium chloride diets from weaning. Rats were weaned at 21 days of age and placed on normal or high sodium chloride diet for 10-12 weeks. At adulthood, the animals were instrumented with brain lateral ventricular cannulas and femoral arterial catheters. Low dose chronic central AII infusion (20 ng min(-1)) significantly (P < 0.05) increased water intake in both groups of rats when compared with their respective controls of 24 h artificial cerebrospinal fluid infusions. In a separate group of high sodium fed rats, coinfusion of AII with the AT1 receptor antagonist, losartan (0.25 microg min(-1)) or the AT2 receptor blocker, PD 123319 (0.50 microg min(-1)) blocked chronic ICV AII-induced drinking. Upon reinfusion of AII water intake increased above control. Following the cessation of AII infusions, water intake returned to values not significantly different from control (P > 0.05). In contrast, in the normal sodium fed rats losartan, but not PD 123319, blocked the AII-mediated water intake. The data demonstrate that in high sodium chloride fed rats AII stimulates both central AT1 and AT2 receptors to induce drinking, while in the normal sodium chloride fed rats the peptide activates the drinking response primarily by stimulation of central AT1 receptors.

Glial angiotensinogen regulates brain angiotensin II receptors in transgenic rats TGR(ASrAOGEN)

TGR(ASrAOGEN)680, a newly developed transgenic rat line with specific downregulation of astroglial synthesis of angiotensinogen, exhibits decreased brain angiotensinogen content associated with a mild diabetes insipidus and lower blood pressure. Autoradiographic experiments were performed on TGR(ASrAOGEN) (TG) and Sprague-Dawley (SD) control rats to quantify AT(1) and AT(2) receptor-binding sites in different brain nuclei and circumventricular organs. Dose-response curves for drinking response to intracerebroventricular injections of ANG II were compared between SD and TG rats. In most of the regions inside the blood-brain barrier [paraventricular nucleus (PVN), piriform cortex, lateral olfactory tract (LOT), and lateral preoptic area (LPO)], AT(1) receptor binding (sensitive to CV-11974) was significantly higher in TG compared with SD. In contrast, in the circumventricular organs investigated [subfornical organ (SFO) and area postrema], AT(1) receptor binding was significantly lower in TG. AT(2) receptors (binding sensitive to PD-123319) were detected at similar levels in the inferior olive (IO) of both strains. Angiotensin-binding sites sensitive to both CV-11974 and PD-123319 were detected in the LPO of SD rats and specifically upregulated in LOT, IO, and most notably PVN and SFO of TG. The dose-response curve for water intake after intracerebroventricular injections showed a higher sensitivity to ANG II of TG (EC(50) = 3.1 ng) compared with SD (EC(50) = 11.2 ng), strongly suggesting that the upregulation of AT(1) receptors inside the blood-brain barrier of TG rats is functional. Finally, we showed that downregulation of angiotensinogen synthesized by astroglial cells differentially regulates angiotensin receptor subtypes inside the brain and in circumventricular organs.

Down-regulation of angiotensin II receptor subtypes and desensitization of cyclic GMP production in neuroblastoma N1E-115 cells

Murine neuroblastoma N1E-115 cells possess membranous receptors for the octapeptide angiotensin II (AngII) whose density is substantially increased by in vitro differentiation. Incubation of differentiated N1E-115 cells with AngII produced a rapid decrease in receptor density, but did not alter the affinity of these receptors for either 125I-AngII or the high-affinity antagonist 125I-[Sarc1,Ile8]-AngII. This apparent down-regulation was dose related with an ED50 of 1 nM, and maximal decreases of approximately 90% were obtained with 100 nM AngII. Receptor loss from differentiated cell membranes was unaffected by incubations of membranes obtained from agonist-exposed cells with non-hydrolyzable analogues of GTP for 60 min at 37 degrees C to ensure dissociation of the ligand. Partial loss of AngII receptors was apparent within 5 min of agonist exposure, whereas maximal declines were not observed until 30 min. This temporal pattern resulted from a preferential decrease in the AT1 receptor subtype during the first 5 min, followed by a decline in both AT1 and AT2 receptors with longer periods of agonist exposure. The loss of membranous receptors was reversible with partial recovery observed after 4 h, and with nearly full recovery observed 18 h after exposure of the cells to AngII. However, the long-term recovery of receptor density was blocked by the protein synthesis inhibitor, cycloheximide. The heptapeptide angiotensin III produced a similar down-regulation of receptors, and the high-affinity antagonist [Sarc1,Thr8]-AngII blocked agonist-induced down-regulation. Finally, the apparent loss of cell surface AngII receptors decreased the ability of AngII to stimulate cyclic GMP production within intact N1E-115 cells.(ABSTRACT TRUNCATED AT 250 WORDS)

Ontogeny of angiotensinogen mRNA and angiotensin II receptors in rat brain and liver

The renin-angiotensin-system (RAS) is active in fetal and neonatal life. This study was undertaken to examine the ontogenic regulation of angiotensinogen (AT) gene expression and angiotensin II (A II) receptors in liver and brain. AT gene expression was studied in fetal, neonatal, adult and aged rats, using slot blot hybridization to quantify AT mRNA levels. During fetal life (gestational days 15-20), AT mRNA was more abundant in brain than in liver. Soon after birth, brain AT mRNA levels increased to a concentration 3 fold above fetal levels. In contrast, liver AT mRNA abundance increased 30-fold within 12 h of birth. Aging (3-20 months) resulted in a gradual decrease in AT mRNA in both the brain and liver. Liver A II receptors in the neonate were 2-fold higher than in the fetus, but returned to fetal levels by 8 weeks of age. In the brain, A II receptor abundance increased to a level 75% above fetal levels in 7 days old animals, but returned to fetal levels by 14 days of age. These studies suggest than in the fetus, the liver is not the primary source of AT but that unknown factors at parturition result in a dramatic increase in liver AT mRNA. In contrast, the more modest increases in brain AT mRNA parallel the gradual maturation of the CNS. In both tissues, further aging resulted in a gradual decrease in AT mRNA, reflecting either increased sensitivity to feedback downregulation by A II or age related increases in other extrahepatic sites of AT synthesis. Age related changes were also found in the A II receptor in both the liver and brain.

Comparative studies of angiotensin II and its analog [Sar1Ala8]angiotensin II on the density of cellular monolayer of cell cultures from green monkey kidney

The effects of the octapeptide angiotensin II (AT II) and its analog [Sar1Ala8]AT II on the cell density in cell culture from green monkey kidney (GMK) were studied. AT II and [Sar1Ala8]AT II provoked a decrease of the number of living cells depending on the concentration (0.001, 0.01 and 0.1 nM) and time of incubation (24, 48 and 72 hours), both peptides having a very similar activity. These data indicate that AT II and [Sar1Ala8]AT II may act on the same class of angiotensin receptors in GMK cells.

Increased blood pressure induced by central application of aminopeptidase inhibitors is angiotensinergic-dependent in normotensive and hypertensive rat strains

Two aminopeptidase inhibitors, amastatin (AM) and bestatin (BE), were employed in 3 strains of rats, spontaneously hypertensive (SHR), Wistar-Kyoto (WKY), and Sprague-Dawley (SD), to investigate the central angiotensinergic system. The results indicate that intracerebroventricular (i.c.v.) injections of AM and BE induced pressor elevations in all 3 strains of rats. In order to test for the possibility of spillage into peripheral vasculature, members from all 3 strains were peripherally infused with AM, BE, or 0.15 NaCl via jugular vein catheters. The SHRs were significantly more responsive to the aminopeptidases than the normotensive strains, however their overall pressor responses were only 33% of those to i.c.v. infusion. Next, in order to test the notion that these aminopeptidase inhibitors are having their effect via the central angiotensinergic system, and not some other peptidergic system, the specific angiotensin receptor antagonist, Sar1, Thr8-AII (sarthran) was employed. Intracerebroventricular pretreatment with sarthran prevented subsequent pressor responses to i.c.v. AM and BE in members of all 3 strains, thereby suggesting that these aminopeptidase inhibitors are having their effect via the central angiotensinergic system.

Monoamine depletion does not alter angiotensin II binding sites in the rat brain

6-Hydroxydopamine (6-OHDA) or 5,7-dihydroxytryptamine (5,7-DHT) was administered in the lateral cerebral ventricles of rats. These respective treatments caused reductions in norepinephrine (NE) and 5-hydroxytryptamine (5-HT) levels in the hypothalamus-thalamus-septum-midbrain (HTSM; 62% and 44%) and brainstem (57% and 26%), respectively. Catecholamine depletion in 6-OHDA-treated rats resulted in a 55% decrease in the pressor response to ICV Ang II which was not associated with any significant change in the binding of 125I-sarcosine1, isoleucine8 Ang II to Ang II binding sites in the HTSM or brainstem. The radioligand binding was not significantly affected by the 5,7-DHT treatment. These results indicate that brain Ang II binding sites are not predominantly localized on NE- or 5-HT-containing nerve terminals. They do not, however, preclude the existence of a small proportion of Ang II binding sites on these neuronal populations.

Effects of phorbol esters and a calcium ionophore on angiotensin II binding in rat brain synaptosomes

In previous studies we determined that protein kinase C (PKC) and calcium are important intracellular regulators of neuronal angiotensin II (Ang II) binding sites. In the present study we investigated the effects of the protein kinase C (PKC) agonist phorbol esters (PE) and also a calcium ionophore (A23187) on the specific binding of [125I]Ang II to brain synaptosomes prepared from rats of different ages. The rationale was to determine whether the large changes in the level of brain Ang II specific binding observed in different age rats are due to changes in the regulation of these sites by PKC or by calcium. The present data indicate no qualitative differences in the effects of PE or A23187 on [125I]Ang II specific binding to hypothalamic or brain stem synaptosomes, from either 2-5 or 70-day-old rats, i.e. the active PE TPA increased while A23187 decreased Ang II binding in all situations. Thus, the dramatic differences in brain Ang II specific binding seen with age appear not to be due to changes in regulation by PKC or calcium.

Tachyphylaxis of dipsogenic activity to intracerebroventricular administration of angiotensins

Repeated intracerebroventricular (i.c.v.) administration of angiotensin II (AII) and angiotensin III (AIII) induced dipsogenic tachyphylaxis in the Sprague-Dawley rat. AIII caused a rapid suppression of drinking, whereas AII showed a progressive decline of water consumption with repeated injections. Tachyphylaxis due to the repeated i.c.v. application of AII failed to abolish subsequent drinking induced by neurotensin or carbachol, suggesting that the tachyphylaxis may be specific to the angiotensinergic system. However, AII-induced tachyphylaxis caused a complete elimination of bestatin-induced drinking which was anticipated given the likelihood that this aminopeptidase B inhibitor has its dipsogenic effect by inhibiting degradation of endogenous angiotensins. Angiotensin-induced tachyphylaxis responses could not be attributed to diminished dipsogenic activity due to volemic expansion of either the cerebroventricular space or gastrointestinal tract. These results concerned with central tachyphylaxis are consistent with previous findings in the periphery and suggest that desensitization of angiotensin receptors occurs in both populations.

Effects of increased circulating angiotensin II (AII) on fluid exchange and binding of AII in the brain

Previous studies have shown that elevated levels of circulating angiotensin II (AII) can influence the binding capacity of this peptide for its receptors in peripheral tissues, but the effect of increased circulating levels of AII on its receptors in the brain has not been well-defined. In the present study, the effect of chronic subcutaneous infusions of AII on: (1) the binding of AII to neuronal membranes from the diencephalon (hypothalamus, thalamus and septum) (HTS) of the brain; (b) water intake and urine output, (c) blood pressure, and (d) their interrelationships was evaluated in rats. Significant increases in daily water intake and urine output accompanied chronic infusions of AII at a rate of 125 ng/kg/min. Both blood pressure and the concentration of aldosterone in plasma were also elevated in these rats. The acute dipsogenic response to either central (10 ng) or peripheral (100 micrograms/kg, SC) administration of AII was also tested both in controls and in rats receiving chronic infusions of AII at a rate of either 40 or 125 ng/kg/min, and no differences were observed. Analysis of the HTS region of the brain revealed a significant increase in the specific binding of AII in AII-infused rats compared to controls. Scatchard analysis of the specific binding of AII to its receptors in the HTS of rats treated with 40 ng AII/kg/min for 6 days revealed a significant increase in the number of binding sites for AII compared to controls (Bmax 12.13 vs. 8.79 fmol/mg protein), but no change in binding affinity (Kd).(ABSTRACT TRUNCATED AT 250 WORDS)

Nodose ganglionectomy reduces angiotensin II receptor binding in the rat brainstem

Angiotensin II (Ang II) receptor binding sites in the dorsomedial medulla of intact and unilaterally nodose ganglionectomized rats were identified and characterized using 125I-sarcosine,isoleucine Ang II. This radioligand bound saturably and with high affinity to rat brain homogenates and to sections of rat brainstem. Specific (1 microM angiotensin II displaceable) binding of 125I-sarcosine,isoleucine Ang II was displaced by angiotensin analogues with a potency order similar to that described for angiotensin II receptors. Unilateral nodose ganglionectomy caused a reduction in Ang II receptor binding in the medial solitary tract nucleus, dorsal motor nucleus of the vagus, and area postrema ipsilateral to the lesioned ganglion. This observation suggests that Ang II receptors in the dorsomedial medulla may be located on axon terminals of vagal afferents and cell bodies of vagal efferents.

Central cardiovascular effects of baclofen in spontaneously hypertensive rats

This study was conducted to investigate the effects of centrally administered baclofen on blood pressure and heart rate in conscious spontaneously hypertensive (SHR) and normotensive Wistar-Kyoto (WKY) rats. Administration of baclofen (1.0 microgram/kg) into the lateral cerebral ventricle (icv) produced an increase in mean arterial pressure (MAP) in both SHR and WKY rats. The increase in MAP was significantly lower in SHR (13 +/- 3 mmHg) when compared with WKY (27 +/- 5 mmHg). The changes in heart rate (HR) were variable, from no change to a very small increase and did not differ significantly between SHR and WKY rats. The ability of baclofen to interfere with baroreceptor reflexes was also tested in separate experiments. In SHR, icv injection of baclofen (1.0 microgram/kg) significantly suppressed the pressor response and bradycardia evoked by phenylephrine 3.0 micrograms/kg iv, whereas in WKY, the pressor and HR responses to similar injections of phenylephrine were not affected by icv baclofen. Similarly, baclofen treatment modified hypotensive response and reflex tachycardia induced by nitroprusside (10.0 micrograms/kg) iv in SHR but not in WKY rats. Administration of sympathetic ganglionic blocker hexamethonium (HEX; 25 mg/kg) iv produced an equivalent decrease in MAP between SHR and WKY following icv injection of baclofen (1.0 microgram/kg). These results suggest that the effects of baclofen on the baroreceptor reflexes in SHR may not be mediated by a change in peripheral sympathetic tone.

Actions of angiotensin on area postrema of the rat

Previous studies have reported that rats drink more saline after area postrema has been removed. The results presented here indicate that prolonged administration of angiotensin II into area postrema of unrestrained rats at 4 pmol/h also caused them to drink more saline. They drank more when angiotensin was released in the anterolateral part of the organ than when it was released anteromedially. Diurnal variation of drinking was not disordered. Dose-response curves showed that rats lacking area postrema drank more saline in response to systemic angiotensin than sham operated animals. The very large 'spontaneous' consumption of saline by rats lacking area postrema was not diminished by saralasin, an angiotensin antagonist. It is concluded that area postrema is a site where systemic angiotensin can act to promote sodium consumption: and that although removing area postrema increases the sensitivity of the drinking response to systemic angiotensin, this enhanced sensitivity is not the cause of the increased sodium consumption.

Effect of intraventricular infusion of an angiotensin II antagonist on 125I-angiotensin II binding in rats

The effects of chronic (six day) intracerebroventricular (i.c.v.) infusion of an angiotensin II antagonist, sarcosine1, isoleucine8 angiotensin II ([Sar1, Ile8]Ang II), (500 ng/microliter per hour) was studied. Specific 125I-Ang II binding site density and binding affinity in the hypothalamus-thalamus-septum-midbrain (H-T-S-M) region of the brain and the adrenal medulla did not differ significantly between [Sar1, Ile8]Ang II treated and control (0.9% saline) rats. However, 125I-Ang II binding to the adrenal cortex was significantly reduced by i.c.v. infusion of [Sar1, Ile8]Ang II. The drinking response to microinjection of Ang II was blunted for up to seven days of [Sar1, Ile8]Ang II infusion. Thus, although [Sar1, Ile8]Ang II effectively blocked the central Ang II receptors, chronic infusion of this Ang II antagonist did not appear to cause alterations in brain H-T-S-M Ang II receptors, suggesting that brain Ang II receptors in normal rats do not undergo homologous regulation.

The effect of removing area postrema on the sodium and potassium balances and consumptions in the rat

Previous studies have indicated that rats lose weight and develop a taste preference for solutions of sodium chloride after area postrema has been removed; results in other species have suggested that area postrema may be concerned with regulating the excretion of sodium and potassium. The results reported here demonstrate that in rats the reduction of weight can be explained adequately by anorexia, that diminished excretion of sodium and potassium results from anorexia, and that the consequent slower rate of gain of weight causes diminution of sodium and potassium balances. The results also show that the rats do not drink more of a solution of sodium chloride because they eat less, and conversely that when they can drink a saline solution they do not eat more: and that they do not drink more saline because of salt loss. Furthermore, individual rats show no significant correlation between the severity of anorexia, and the increased consumption of saline. Taken together the results suggest that primary disorder of regulation of intake occurs in rats after area postrema has been removed, and that the reduced intake of food and the increased intake of sodium chloride occur independently.

Increased angiotensin II binding affinity in the nucleus tractus solitarius of spontaneously hypertensive rats

Angiotensin II (Ang) binding kinetics were determined in discrete brainstem nuclei of 14-week-old spontaneously hypertensive rats (SHR) and normotensive Wistar-Kyoto rats (WKY) by a quantitative autoradiographic technique. Tissue sections were incubated with 125I-labeled [sarcosine-1]Ang, and results were analyzed by computerized densitometry and comparison to 125I-labeled standards. A single class of high-affinity binding sites was identified in the nucleus tractus solitarius, the area postrema, and the inferior olivary nuclei of both SHR and WKY rats. Ang binding affinity was significantly greater in the nucleus tractus solitarius of SHR compared to normotensive WKY rats (0.27 +/- 0.06 X 10(9) M-1 in WKY rats vs. 0.59 +/- 0.15 X 10(9) M-1 in SHR), with no apparent changes in the maximum binding capacity of this area. There were no changes in the Ang binding kinetics of the area postrema or the inferior olivary nuclei. Our results suggest that central Ang activity is altered in established hypertension in a brainstem area of SHR associated with peripheral cardiovascular control.

Angiotensin II receptor localization in the canine CNS

Specific binding of [125I]angiotensin II [(125I]Ang II) to sections of dog brain was determined by in vitro receptor autoradiography. Highly discrete, dark images representing specific binding of [125I]Ang II were observed in areas corresponding to the nucleus of the solitary tract, dorsal motor nucleus of the vagus, area postrema, ventrolateral medulla, pineal, subfornical organ, nucleus medianus, septum, organum vasculosum of the lamina terminalis and the anterior pituitary. The specific binding was frequently present either as a narrow band or tiny spot within a small portion of the nuclei to which the binding corresponded. The location of these Ang II recognition sites in regions associated with regulation of autonomic and neuroendocrine function provides further evidence for a role of this peptide within the central nervous system.